Piper Sandler lowered the firm’s price target on Nevro to $34 from $37 and keeps an Underweight rating on the shares post the Q1 results. The analyst is encouraged to see some early recovery in the broader spinal cord stimulation market, but says the market still has a ways to go to get back to pre-pandemic levels. The firm sees a more competitive market taking shape over the next 12-18 months.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVRO:
- Nevro price target raised to $76 from $72 at Canaccord
- Nevro backs FY23 revenue view $445M-$455M, consensus $448.91M
- Nevro sees Q2 $110M-$112M, consensus $111.52M
- Nevro reports Q1 EPS (98c), consensus ($1.04)
- Nevro Reports First Quarter 2023 Financial Results, Provides Second Quarter Guidance and Reiterates Full-Year 2023 Guidance
